CompletedNot Applicable

A Study of MIRCERA for the Intrapetient Variability of Hemoglobin Levels in Patients With Chronic Renal Anemia (RIVAL)

Greece1,288 participantsStarted 2010-09-30

Plain-language summary

This retrospective observational study will assess the incidence of hemoglobin cycling in chronic kidney disease (stage 3, 4, and 5) patients with renal anemia treated with Mircera (methoxy polyethylene glycol-epoetin beta). Data will be collected from each patient from a 9-month treatment period.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patients, \>/= 18 years of age * Chronic kidney disease in predialysis (stage 3 and 4) and dialysis * Renal anemia treated with Mircera according to label for at least 9 months before date of signed informed consent Exclusion Criteria: * Participation in an interventional clinical trial within the retrospective observation period * Contraindications to Mircera administration as per label or judged by the investigator

What they're measuring

Percentage of Participants With at Least One Hemoglobin Cycling

Timeframe: 9 months

Trial details

NCT IDNCT01356589

SponsorHoffmann-La Roche

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2012-07-31

Results submitted2015-11-23

View on ClinicalTrials.gov More Anemia trials